May 7, 2021 10:44 AM EDTUpdated 10:57 AM

Incyte ponies up $12M to settle charity foundation kickback claims; US exercises option for more doses of monkeypox vaccine

Kyle Blankenship

Zachary Brennan

Senior Editor

Nicole DeFeudis

Editor

One in a string of lawsuits targeting copay charity foundations, the DOJ has been hunting drugmaker Incyte for what prosecutors alleged was a kickback scheme …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Incyte ponies up $12M to settle charity foundation kickback claims; US exercises option for more doses of monkeypox vaccine

Kyle Blankenship

Zachary Brennan

Senior Editor

Nicole DeFeudis

Editor

Sign up to read this article for free.

Among pharma CEOs, the IRA now and the IRA later get very different reactions

Bristol Myers restarts radiopharmaceutical Phase 3 trial, but delays readout by one year

Updated: With cost-cutting underway, Bristol Myers raises guidance, touts Phase 3 win and scraps another

Andrew Left, short seller who campaigned against Valeant, is accused of fraud by SEC

European drug regulator rejects Alzheimer's drug Leqembi, citing safety concerns

Critical Junctures in Gene Therapy Clinical Material Manufacturing: Where Do I Start? And Will It Work?

In­cyte ponies up $12M to set­tle char­i­ty foun­da­tion kick­back claims; US ex­er­cis­es op­tion for more dos­es of mon­key­pox vac­cine

Senior Editor

Editor

Sign up to read this article for free.

Incyte ponies up $12M to settle charity foundation kickback claims; US exercises option for more doses of monkeypox vaccine